What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to report Eli Lilly's financial results for the first quarter ended March 31, 2009, and to provide updated financial expectations for the full year 2009. A key aspect is the company's explanation of its use of pro forma non-GAAP financial measures.

Why is Eli Lilly using non-GAAP financial measures in its reporting?

Eli Lilly uses pro forma non-GAAP measures to offer investors a clearer view of its ongoing operational performance and trends. These measures exclude significant, often volatile, items from prior periods (like tax benefits, restructuring charges, and acquisition-related costs) and adjust for the timing of the ImClone acquisition, allowing for more meaningful period-over-period comparisons.

How does the acquisition of ImClone Systems impact the reported results?

The acquisition of ImClone Systems, which closed in late November 2008, is accounted for by presenting pro forma results as if the acquisition had occurred on January 1, 2008. This retrospective adjustment helps in comparing the 2009 performance against a more comparable 2008 operational baseline, excluding the partial-year impact of ImClone in 2008.

What specific types of items are excluded in the non-GAAP adjustments?

The excluded items are typically irregular and difficult to predict, such as tax benefits from IRS audits, charges related to the termination of development programs (e.g., AIR Insulin), acquisition-related expenses (including in-process R&D), asset impairments, restructuring and exit costs, and charges related to legal investigations and settlements (e.g., Zyprexa).

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on April 20, 2009, to report its first-quarter 2009 results and provide financial expectations for the full year. The filing primarily details the company's use of pro forma non-GAAP financial measures, which adjust for significant one-time items and the assumed retrospective acquisition of ImClone Systems. This approach aims to provide investors with a clearer view of ongoing operational performance and trends by excluding items like tax benefits from IRS audits, restructuring charges, asset impairments, in-process R&D, and the impact of legal settlements related to Zyprexa. The company highlighted its use of these non-GAAP measures to facilitate meaningful period-over-period comparisons, particularly in light of the ImClone acquisition completed in late 2008. By restating prior periods as if ImClone had been acquired earlier, Lilly seeks to present a more consistent operational narrative. Investors are encouraged to consider these non-GAAP figures alongside traditional GAAP measures for a comprehensive understanding of the company's financial health and future outlook.

Key Highlights

1Eli Lilly reported its Q1 2009 results on April 20, 2009, via an 8-K filing.
2The company utilized pro forma non-GAAP financial measures to present its Q1 2009 results and full-year 2009 financial expectations.
3Non-GAAP adjustments exclude significant items such as tax benefits, restructuring costs, asset impairments, and R&D charges from prior periods (2008).
4The ImClone Systems acquisition, completed in November 2008, was retroactively applied to January 1, 2008, for pro forma comparisons.
5LLY aims to provide investors with enhanced insight into ongoing operational trends and performance by excluding volatile and unpredictable items.
6The filing confirmed the company's financial expectations for 2009, including both GAAP and pro forma non-GAAP earnings per share.
7Investors are advised to consider these non-GAAP measures in conjunction with, not as a substitute for, GAAP financial statements.

ELI LILLY & Co 8-K Report, Financial Results (Apr 20, 2009)

Summary

Key Highlights

Frequently Asked Questions